Accelerating the preventive drug treatment of people infected with latent tuberculosis (LTBI) is a high priority to eradicate TB disease and a focus of the ‘We Can #EndTB’ campaign.
To achieve this ambitious goal, diagnostic tests are urgently needed to screen latent tuberculosis LTBI and determine who will progress to active TB disease.
Phage-based diagnostics offer the ability to differentiate between active and past infections.
However, a broader understanding of the LTBI diagnostic landscape is needed to support wider implementation of LTBI treatment with new diagnostics.
They will review the epidemiology of TB and limitations of current tests that look at host response. They will also explain how, by enabling direct detection of the pathogen in the blood, phage-based diagnostics provide the opportunity to determine incipient/subclinical disease, as demonstrated in recent clinical trials.
The webinar ‘Phage-Based Laboratory Diagnostics Role in the Detection of Tuberculosis’ will be hosted by the American Association of Clinical Chemistry (AACC) on 19 April 2023 from 12 – 1 PM (Eastern Time) (5 – 6 PM BST).
It will feature:
- Dr Pranabashis Haldar, Clinical Senior Lecturer and Honorary Consultant Physician in Respiratory Medicine for National Institute for Health Research Respiratory Biomedical Research Centre at University of Leicester, UK.
- Dr Tony Hu, Weatherhead Presidential Chair in Biotechnology Innovation Professor of Biochemistry and Molecular Biology, Microbiology, and Biomedical Engineering at School of Medicine, Tulane University, USA.
There will be an opportunity for live Q&A with the speakers.
To participate in the webinar visit https://www.aacc.org/education/all-webinars
More about phage-based diagnostics for TB detection.